Product Information
CETIRIZINE-PSE ER 5-120 MG TAB is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.5625 per EA under NDC 45802014753. Its NADAC has been published 334 times since May 13, 2020.
FDA first approved this application on Nov 16, 2018.
Strength
5; 120 mg/1; mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802014753
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210719FDA Approved
11/16/2018
On Market Since
3/31/2020
Pharmacological Classes
Price Statistics
The NADAC for CETIRIZINE-PSE ER 5-120 MG TAB has been published 334 times since May 13, 2020, and over the history we have for it it has declined 16.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5625 per EA |
|---|---|
| All-time high | $0.7274 (Apr 14, 2021) |
| All-time low | $0.5313 (Nov 20, 2024) |
| 52-week high | $0.5956 |
| 52-week low | $0.5617 |
| Median price | $0.5957 |
| Average price | $0.6008 |
| Largest weekly change | +18.9% (Mar 17, 2021) |
| Weeks tracked | 334 |
| Tracking since | May 13, 2020 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cetirizine hydrochloride, Pseudoephedrine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CETIRIZINE-PSE ER 5-120 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CETIRIZINE-PSE ER 5-120 MG TAB, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.5625 per EA (NDC 45802014753), effective Sep 30, 2026.
How has the price of CETIRIZINE-PSE ER 5-120 MG TAB changed over time?
Over the history we have for it, the NADAC for CETIRIZINE-PSE ER 5-120 MG TAB has declined 16.6%. It has been tracked across 334 weekly CMS publications since May 13, 2020.
What are the highest and lowest recorded NADAC prices for CETIRIZINE-PSE ER 5-120 MG TAB?
Since May 13, 2020, the NADAC for CETIRIZINE-PSE ER 5-120 MG TAB has ranged from a low of $0.5313 (Nov 20, 2024) to a high of $0.7274 (Apr 14, 2021), with a median of $0.5957 per EA.
Are there cheaper alternatives to CETIRIZINE-PSE ER 5-120 MG TAB?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CETIRIZINE-PSE ER 5-120 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CETIRIZINE-PSE ER 5-120 MG TAB?
CETIRIZINE-PSE ER 5-120 MG TAB (NDC 45802014753) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.